Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclo(L-leucyl-L-prolyl)
- Development stage
- Preclinical
- Lead developer
- Alagappa University
- Modality
- Small Molecules, Peptides
- Administration
- Oral, Topical
01
Overview
cyclo(L-leucyl-L-prolyl) (also known as gancidin W) is a naturally occurring cyclic dipeptide (diketopiperazine) produced by various bacteria and fungi, including marine-derived *Bacillus amyloliquefaciens* and *Streptomyces* species. It exhibits broad-spectrum antimicrobial, antifungal, and antivirulence properties. In *Candida albicans*, cyclo(L-leucyl-L-prolyl) acts as a non-fungicidal antivirulence agent that inhibits biofilm formation, yeast-to-hypha transition, and germ-tube formation by targeting the Ras1-Cyr1-Pka-Efg1 signaling pathway, making it a promising candidate for the management of Candida-associated denture stomatitis. Additionally, it has been shown to target the tetraspanin CD151, disrupting its interaction with EGFR and thereby inhibiting the migration and invasion of triple-negative breast cancer cells. It also exhibits antimalarial activity against *Plasmodium berghei*.
- Other names
- cis-cyclo(L-Leu-L-Pro)cyclo(L-Leu-L-Pro)cyclo(L-prolyl-L-leucyl)cyclo(Leu-Pro)gancidin WL-leucyl-L-proline lactamL-leucyl-L-prolyl lactammaculosin 6maculosin6maculosin-6
02
Targets
CD151 (CD151 molecule (Raph blood group))RAS family (RAS small GTPase family)AC (Adenylyl cyclase family)EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on cyclo(L-leucyl-L-prolyl).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclo(L-leucyl-L-prolyl).